What Is Fibromyalgia: Widespread Pain, Diagnosis, and Management

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice, diagnosis, or treatment.

What Is Fibromyalgia?

Fibromyalgia is a chronic, widespread pain condition characterized by amplified pain processing in the central nervous system, fatigue, sleep disturbances, and cognitive difficulties, in the absence of identifiable inflammatory, structural, or metabolic tissue pathology. It is one of the most common chronic pain conditions worldwide, affecting approximately 2–4% of the global population — an estimated 200 million people. Women are diagnosed 2–3 times more frequently than men, though this disparity may partly reflect diagnostic biases and gender differences in pain reporting rather than true prevalence differences. Fibromyalgia typically emerges between ages 30 and 55, though it can occur at any age, including in children.

Fibromyalgia is not a diagnosis of exclusion in the traditional sense; rather, it has positive diagnostic criteria and a well-characterized neurobiological basis — central sensitization. The condition exists on a spectrum with other central sensitivity syndromes, including irritable bowel syndrome (IBS), chronic fatigue syndrome/ME, interstitial cystitis, and tension-type headache, which frequently co-occur.

The Neurobiology: Central Sensitization

The defining feature of fibromyalgia is central sensitization — an amplification of neural signaling within the central nervous system (spinal cord and brain) that magnifies pain perception. Functional MRI studies consistently demonstrate that fibromyalgia patients show greater activation of pain-processing brain regions (anterior cingulate cortex, somatosensory cortex, insula) in response to stimuli that are non-painful or only mildly painful in controls. This lowered pain threshold (allodynia — pain from normally non-painful stimuli) and augmented pain response (hyperalgesia — exaggerated pain from painful stimuli) are measurable with quantitative sensory testing.

Key neurobiological mechanisms include:

• Elevated pro-nociceptive neurotransmitters: Studies show elevated levels of substance P (a pain-amplifying neuropeptide) and glutamate in the cerebrospinal fluid of fibromyalgia patients, lowering the threshold for pain signaling.
• Reduced descending inhibition: The brain normally dampens pain through descending inhibitory pathways using serotonin, norepinephrine, and endogenous opioids. In fibromyalgia, this conditioned pain modulation (CPM) — the body's diffuse noxious inhibitory control — is demonstrably impaired in experimental studies.
• Altered brain connectivity: Resting-state fMRI reveals abnormal connectivity between the default mode network and pain-processing regions, suggesting altered interoceptive processing and attention to bodily sensations.

Symptoms

Diagnosis

The 2016 American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia replaced the outdated tender-point examination with a symptom-based approach:

• Widespread Pain Index (WPI): Count of body regions (from a list of 19) where the patient has had pain in the last week. Score ranges 0–19.
• Symptom Severity Scale (SSS): Rates fatigue, waking unrefreshed, and cognitive symptoms (each 0–3), plus severity of somatic symptoms (0–3). Total 0–12.

Diagnosis requires: (WPI ≥7 AND SSS ≥5) OR (WPI 4–6 AND SSS ≥9), symptoms present for at least 3 months, and the diagnosis is appropriate regardless of other diagnoses (fibromyalgia frequently co-exists with rheumatoid arthritis, lupus, and osteoarthritis). Laboratory and imaging tests are used to exclude other conditions (thyroid disorders, inflammatory arthritis, vitamin D deficiency) rather than to confirm fibromyalgia itself.

Management: A Multimodal Approach

Evidence strongly supports a multimodal, patient-centered approach combining education, exercise, psychological interventions, and pharmacotherapy. No single treatment is universally effective, and combinations tailored to the individual's dominant symptoms produce the best outcomes.

Non-Pharmacological Treatments

• Aerobic exercise: The most consistently effective intervention — improves pain, fatigue, mood, and quality of life. Effect sizes are moderate. Low-impact activities (walking, swimming, cycling) are preferred initially; gradual progression is essential because post-exertional malaise can lead to overexertion and symptom flares.
• Cognitive-Behavioral Therapy (CBT): CBT targeting pain catastrophizing, fear-avoidance, and sleep hygiene is effective for pain, function, and mood. Pain catastrophizing — the tendency to magnify and helplessly ruminate about pain — is one of the strongest predictors of fibromyalgia severity.
• Mindfulness-Based Stress Reduction (MBSR): Reduces pain catastrophizing and improves quality of life; neuroimaging studies show MBSR reduces pain-related brain activation.

Pharmacological Treatments

Opioids are generally not recommended for fibromyalgia — there is no consistent evidence of benefit, and they can paradoxically worsen central sensitization through opioid-induced hyperalgesia. NSAIDs have limited efficacy because fibromyalgia is not primarily an inflammatory condition. Long-term management requires ongoing reassessment and adjustment of the treatment plan.